Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.

Zabaleta N, Barberia M, Martin-Higueras C, Zapata-Linares N, Betancor I, Rodriguez S, Martinez-Turrillas R, Torella L, Vales A, Olagüe C, Vilas-Zornoza A, Castro-Labrador L, Lara-Astiaso D, Prosper F, Salido E, Gonzalez-Aseguinolaza G, Rodriguez-Madoz JR.

Nat Commun. 2018 Dec 21;9(1):5454. doi: 10.1038/s41467-018-07827-1.

2.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

PMID:
30563891
3.

Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.

Rabal O, San José-Enériz E, Agirre X, Sánchez-Arias JA, Vilas-Zornoza A, Ugarte A, de Miguel I, Miranda E, Garate L, Fraga M, Santamarina P, Fernandez Perez R, Ordoñez R, Sáez E, Roa S, García-Barchino MJ, Martínez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.

J Med Chem. 2018 Aug 9;61(15):6518-6545. doi: 10.1021/acs.jmedchem.7b01926. Epub 2018 Jul 19.

PMID:
29953809
4.

Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells.

Garitano-Trojaola A, José-Enériz ES, Ezponda T, Unfried JP, Carrasco-León A, Razquin N, Barriocanal M, Vilas-Zornoza A, Sangro B, Segura V, Prósper F, Fortes P, Agirre X.

Oncotarget. 2018 Feb 5;9(16):12842-12852. doi: 10.18632/oncotarget.24401. eCollection 2018 Feb 27.

5.

Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome.

Rodriguez-Madoz JR, San Jose-Eneriz E, Rabal O, Zapata-Linares N, Miranda E, Rodriguez S, Porciuncula A, Vilas-Zornoza A, Garate L, Segura V, Guruceaga E, Agirre X, Oyarzabal J, Prosper F.

PLoS One. 2017 Dec 27;12(12):e0190275. doi: 10.1371/journal.pone.0190275. eCollection 2017.

6.

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.

San José-Enériz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, Ugarte A, Roa S, Paiva B, Estella-Hermoso de Mendoza A, Alvarez RM, Casares N, Segura V, Martín-Subero JI, Ogi FX, Soule P, Santiveri CM, Campos-Olivas R, Castellano G, de Barrena MGF, Rodriguez-Madoz JR, García-Barchino MJ, Lasarte JJ, Avila MA, Martinez-Climent JA, Oyarzabal J, Prosper F.

Nat Commun. 2017 May 26;8:15424. doi: 10.1038/ncomms15424.

7.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

8.

Use of human pharyngeal and palatine tonsils as a reservoir for the analysis of B-cell ontogeny in 10 paired samples.

Pascual M, Alignani D, Vilas-Zornoza A, Delgado JA, Vázquez I, Malumbres R, Rodriguez I, Barriuso R, Calasanz MJ, Paiva B, Agirre X, Prósper F, Cervera-Paz FJ.

Clin Otolaryngol. 2016 Oct;41(5):606-11. doi: 10.1111/coa.12540. Epub 2016 Feb 8. No abstract available.

PMID:
26384863
9.

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.

Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, José-Eneriz ES, Miranda E, Martín-Subero JI, Garate L, Blanco-Prieto MJ, García de Jalón JA, Rio P, Rifón J, Cigudosa JC, Martinez-Climent JA, Román-Gómez J, Calasanz MJ, Ribera JM, Prósper F.

Leukemia. 2012 Jul;26(7):1517-26. doi: 10.1038/leu.2012.31. Epub 2012 Feb 6.

10.

Development and validation of ultra high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues.

Estella-Hermoso de Mendoza A, Imbuluzqueta I, Campanero MA, Gonzalez D, Vilas-Zornoza A, Agirre X, Lana H, Abizanda G, Prosper F, Blanco-Prieto MJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3490-6. doi: 10.1016/j.jchromb.2011.09.029. Epub 2011 Sep 22.

PMID:
21983199
11.

Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family.

Rodriguez-Otero P, Román-Gómez J, Vilas-Zornoza A, José-Eneriz ES, Martín-Palanco V, Rifón J, Torres A, Calasanz MJ, Agirre X, Prosper F.

Br J Haematol. 2011 Oct;155(1):73-83. doi: 10.1111/j.1365-2141.2011.08812.x. Epub 2011 Aug 2.

PMID:
21810092
12.

Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.

Vilas-Zornoza A, Agirre X, Martín-Palanco V, Martín-Subero JI, San José-Eneriz E, Garate L, Álvarez S, Miranda E, Rodríguez-Otero P, Rifón J, Torres A, Calasanz MJ, Cruz Cigudosa J, Román-Gómez J, Prósper F.

PLoS One. 2011 Feb 28;6(2):e17012. doi: 10.1371/journal.pone.0017012.

13.

Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia.

Martín V, Valencia A, Agirre X, Cervera J, San Jose-Eneriz E, Vilas-Zornoza A, Rodriguez-Otero P, Sanz MA, Herrera C, Torres A, Prosper F, Román-Gómez J.

Cancer Sci. 2010 Feb;101(2):425-32. doi: 10.1111/j.1349-7006.2009.01413.x. Epub 2009 Oct 29.

14.

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.

San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodríguez-Otero P, Calasanz MJ, Prósper F, Agirre X.

Mol Cancer. 2009 Sep 1;8:69. doi: 10.1186/1476-4598-8-69.

15.

Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.

Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martin-Subero JI, Cordeu L, Gárate L, San José-Eneriz E, Abizanda G, Rodríguez-Otero P, Fortes P, Rifón J, Bandrés E, Calasanz MJ, Martín V, Heiniger A, Torres A, Siebert R, Román-Gomez J, Prósper F.

Cancer Res. 2009 May 15;69(10):4443-53. doi: 10.1158/0008-5472.CAN-08-4025. Epub 2009 May 12.

16.

Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.

Roman-Gomez J, Agirre X, Jiménez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P, Martin-Subero I, Garate L, Cordeu L, San José-Eneriz E, Martin V, Castillejo JA, Bandrés E, Calasanz MJ, Siebert R, Heiniger A, Torres A, Prosper F.

J Clin Oncol. 2009 Mar 10;27(8):1316-22. doi: 10.1200/JCO.2008.19.3441. Epub 2009 Jan 21.

PMID:
19164206
17.

Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.

Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, Prósper F.

Mol Cancer Res. 2008 Dec;6(12):1830-40. doi: 10.1158/1541-7786.MCR-08-0167.

18.

Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia.

Martin V, Agirre X, Jiménez-Velasco A, José-Eneriz ES, Cordeu L, Gárate L, Vilas-Zornoza A, Castillejo JA, Heiniger A, Prósper F, Torres A, Roman-Gomez J.

Cancer Sci. 2008 Sep;99(9):1865-8. doi: 10.1111/j.1349-7006.2008.00884.x. Epub 2008 Jun 28.

19.

WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia.

Roman-Gomez J, Jimenez-Velasco A, Cordeu L, Vilas-Zornoza A, San Jose-Eneriz E, Garate L, Castillejo JA, Martin V, Prosper F, Heiniger A, Torres A, Agirre X.

Eur J Cancer. 2007 Dec;43(18):2736-46.

PMID:
18032022

Supplemental Content

Loading ...
Support Center